Cross-linked Polymeric Nanoparticles for Poorly Water-Soluble Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems for poorly water-soluble medicines face challenges such as instability in vivo, drug leakage, cytotoxicity due to surfactants, limited bioavailability, and inability to target specific tissues, particularly for oral delivery and systemic circulation.
Innovation Solution
Development of cross-linked polymeric nanoparticles with a hydrophobic core and hydrophilic shell, incorporating N-isopropylacrylamide, vinyl compounds, and acrylic acid, which can be functionalized with PEG chains for long circulation and targeting, enabling controlled release and enhanced bioavailability for oral and systemic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If surfactant-based emulsion systems are used to solubilize poorly water-soluble drugs, then drug solubility is improved, but in vivo stability deteriorates and drug leakage occurs
Solution Approach 1:
The patent uses a composite polymeric nanoparticle system combining hydrophobic core materials (for drug encapsulation) and hydrophilic shell materials (for stability and solubility). This composite structure resolves the contradiction by providing both drug solubility enhancement through the hydrophobic core and in vivo stability through the hydrophilic shell that prevents aggregation and leakage.
Solution Approach 2:
The nanoparticle is segmented into distinct functional regions: a hydrophobic core for drug loading and a hydrophilic shell for stability. This segmentation allows each region to independently address its specific function - the core maximizes drug solubility while the shell ensures in vivo stability, resolving the contradiction between solubility enhancement and stability maintenance.
2Quantity of substance
If conventional emulsion systems are used for drug delivery, then drug loading is achieved, but cytotoxicity increases due to surfactant disruption of biological membranes
Solution Approach 1:
The patent extracts and eliminates harmful surfactant components from conventional emulsion systems, replacing them with biocompatible polymeric materials. This removal of toxic surfactants while retaining drug loading capability through the hydrophobic core resolves the contradiction between achieving drug loading and minimizing cytotoxicity.
Solution Approach 2:
The patent changes the material parameters from conventional surfactants to biocompatible polymeric materials with appropriate hydrophobicity and biodegradability characteristics. This parameter change maintains drug loading efficiency while eliminating the cytotoxic effects associated with surfactant membrane disruption.
3Ease of operation
If non-targeted drug delivery systems are used, then general distribution is achieved, but site-specific delivery capability is lost
Solution Approach 1:
The polymeric nanoparticle platform provides multi-functionality by combining passive targeting (through size-dependent EPR effect for general distribution) with active targeting capabilities (through surface functionalization with targeting ligands). This universality resolves the contradiction by enabling both broad distribution and site-specific delivery depending on the application requirements.
Solution Approach 2:
The nanoparticle system is designed to be dynamic and adaptable - the surface can be functionalized with different targeting ligands depending on the target site, and the particle size can be optimized for different distribution patterns. This dynamic adaptability allows the system to switch between general distribution and site-specific delivery modes.
4Quantity of substance
If polymeric micelles are used for parenteral delivery, then solubilization of hydrophobic drugs is improved, but oral bioavailability is limited
Solution Approach 1:
The patent modifies key parameters of polymeric micelles including surface charge, hydrophilicity, and molecular weight to enhance oral bioavailability. By adjusting these parameters, the nanoparticles can withstand gastrointestinal conditions and facilitate mucosal penetration, resolving the contradiction between maintaining drug solubilization and improving oral delivery performance.
Solution Approach 2:
The patent develops composite polymeric nanoparticles that combine the solubilization advantages of polymeric micelles with additional functional components for oral delivery enhancement, such as mucoadhesive polymers and pH-responsive materials. This composite approach maintains hydrophobic drug solubilization while adding capabilities for improved oral bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively solubilize and deliver poorly water-soluble drugs, achieving high bioavailability and targeted delivery with minimal toxicity, as demonstrated by enhanced blood levels and efficacy in cancer and bacterial models, while maintaining stability at body temperature.
Implementation Method 1
cross-linked polymeric nanoparticles with a hydrophobic core and hydrophilic shell
Implementation Method 2
cross-linked polymeric nanoparticles with a hydrophobic core and hydrophilic shell
Implementation Method 3
cross-linked polymeric nanoparticles... enabling controlled release
Data Source
AI summary
Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropylacrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpryolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivatives like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%; and acrylic acid (AA), at a molar ration of about 10% to about 30%.